Annovis Bio (FRA:07X) Short Percentage of Float


FRA:07X Annovis Bio Inc FRA:07X
33 GF Score
Price €1.49
! 1 Warning Sign
View Full Analysis

What is Annovis Bio Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:07X vs HYFT, EXOZ, ACRV: Short Percentage of Float Comparison

For the Biotechnology subindustry, Annovis Bio's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annovis Bio Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Annovis Bio's Short Percentage of Float falls into.


FRA:07X
33GF Score
Annovis Bio Inc FRA:07X
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
33GF Score

Get the complete analysis for FRA:07X

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.49
Price